Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I-II Clinical Trial for the Evaluation of Brentuximab Vedotin Plus Etoposide, Solumoderin (Methylprednisolone), High Dose ARA-C (Cytarabine) and Cisplatin in the Transplant and Post-transplant Management for Relapsed or Refractory Classical Hodgkin Lymphoma Patients

NCT02243436 is registered in ClinicalTrials.gov with Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea as lead sponsor.

NCT NCT02243436
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02243436 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I-II Clinical Trial for the Evaluation of Brentuximab Vedotin Plus Etoposide, Solumoderin (Methylprednisolone), High Dose ARA-C (Cytarabine) and Cisplatin in the Transplant and Post-transplant Management for Relapsed or Refractory Classical Hodgkin Lymphoma Patients
Lead sponsor
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase
Phase 1/2
Overall status
Completed
Start date
November 11, 2014
Completion date
January 14, 2019
Enrollment
67 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

classical hodgkin lymphoma